Form 4: Beam Therapeutics CLO Sells Shares for Tax Obligations

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 1,254 shares of common stock at $27.1 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Christine Bellon, Chief Legal Officer and Director of Beam Therapeutics Inc. (BEAM), reported a transaction involving the company's common stock.
• On December 31, 2025, Bellon disposed of 1,254 shares of common stock at a price of $27.1 per share.
• The sale was non-discretionary and executed to cover tax withholding obligations upon the vesting of restricted stock units (RSUs) granted on December 30, 2022.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Bellon on May 19, 2023.
• Following this transaction, Christine Bellon beneficially owns 115,667 shares of Beam Therapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax obligations, which is a neutral event and does not indicate positive or negative sentiment towards the company's performance or prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor, routine disposition of shares by a key executive, unlikely to have a significant impact on shareholder sentiment or the company's stock price.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1, Christine Bellon